Ohio State Navbar

Directory

Rebecca Klisovic, MD


Staff photo

320 W 10th Ave
Columbus, OH 43210

Phone: (614) 366-3802

Email: klisovic.3@osu.edu

 

Current OSU Appointments

Associate Professor-Clinical, Hematology

Physician, FGP-Hematology

 

Academic Advising

2004 - 2005 Jacob The Ohio State University.
2007 - 2008 Stephen The Ohio State University.
2008 - 2012 Alice Mims The Ohio State University. Graduated 2012.
 

Certifications

1991 - present American Board of Internal Medicine/Certified Internal Medicine: American Board of Internal Medicine
1998 - present North Carolina State License: University of North Carolina
2001 - present Ohio State License: The Ohio State University
2004 - present Americal Board of Internal Medicine/Certified Medical Oncology (#196433): American Board of Internal Medicine
 

Clinical Services

09/01/2001 Outpatient Clinic (Hematology)
07/01/2004 HEM II In Patient Service (James Cancer Hospital)
09/01/2004 HEM III (HNP) In patient Service (James Cancer Hospital, Hematology)
05/01/2007 Blood and Marrow Transplantation (BMT) Inpatient Service (James Cancer Hospital)

Clinical Trials

CALGB-9665 Leukemia Tissue Bank [Dr. Michael Caligiuri, National Study Chair]

Cytogenetic Studies in Acute Leukemia [Dr. Clara Bloomfield, National Study Chair]

OSU 0304: A phase I study of GTI-2040 in combination with high dose cytarabine in patients with relapsed or refractory acute myeloid leukemia

CALGB-100103 A Phase II Study of Allogeneic Transplant for Older Patients with AML in CR1 Using a Non-Myeloablative Preparative Regimen

CALGB-10201 A Phase III Study of Daunorubicin and Cytarabine +/- G3139 (Genasense, Oblimersen Sodium, NSC # 683428, IND # 58842), A BCL2 Antisence Oligodeoxynucleotide, in Previously Untreated Patients with Acute Myeloid Leukemia (AML) >/= 60 Years

OSU-05061 Molecular Studies in Acute Myeloid Leukemia

CALGB 10303: A Phase IIb Study Of Molecular Responses To Imatinib, At Standard Or Increased Doses, or Dasatinib For Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) In Chronic Phase.

OSU-05055 A phase I study of MLN518 given in combination with standard induction chemotherapy for the treatment of patients with newly diagnosed acute myelogenous leukemia

OSU 05104: A phase I trial of AVN-944 in patients with advanced hematologic malignancies.

OSU-06003 Phase I Study of Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.

OSU 06109: A phase II study of decitabine in myelofibrosis.

OSU-07028 A phase II trial of GTI-2040 in combination with (HiDAC) in refractory and relapsed acute myeloid leukemia (AML)

OSU-07017 Phase II Study of Decitabine in Acute Myeloid Leukemia

OSU-06042 A Multicenter, Prospective Trial to Evaluate the Role of NK Cell Kir Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation from HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies.

OSU-06101 A Phase II Study of MGCD0103 (MG-0103) in Patients with Acute Myelogenous Leukemia/High Risk MDS Who are Elderly and Have Previously Untreated Disease or Who are Adult and Have Relapsed/Refractory Disease

A Phase II Simon Two-Stage Multicenter Study and Pilot Pharmacodynamic Investigation of GTI-2040 in Combination with High Dose Cytarabine (HiDAC) in Refractory and Relapsed Acute Myeloid Leukemia (AML)

OSU-07066 A phase I combination trial of SGN-33 (antihuCD33 mAb; HuM195; lintuzmab) and lenlidomide (revlimid) in patients with myelodysplastic syndromes

CALGB- 10503 Phase II study of maintenance therapy with decitabine following standard induction and cytogenetic risk-adpated intensification in previously untreated patients with AML <60 years

MPD-RC 107: Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD

MPD-RC 106: MPD-RC Research Tissue Bank

MPD-RC 104: A Multicenter, Open Label Phase I/II Study of CEP701 in Adults with Myelofibrosis

MPD-RC 101: Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis.

CALGB-20202 Assessment of Novel Molecular Markers in Acute Myeloid Leukemia

OSU-08047 Phase I Study of Decitabine (Dacogen) and Bortezomib (Velcade) in Acute Myeloid Leukemia

SWOG-S0521 A Randomized Trial of maintenance vs.observation for patients with previously untreated low and intermediate risk APL, Phase III

OSU-08066 DFCI ALL Adult Consortium Protocol: Adult ALL Trial

CALGB-10603 A Phase III Randomized, double-blind study of induction(Daunorubicin/Cytarabine) and Consoldiation(High Dose Cytarabine)Chemotherapy+Midastraurin(PKC412)(IND#101261) or Placebo in newly diagnosed patients <60yrs of age with FLT3 Mutated AML

OSU-07071 Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Patients with Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

CALGB-10403 Intergroup Phase II clinical Trial for Adolescents and young adults(<30yrs) in untreated ALL

OSU-07068 Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD

OSU-07095 Phase I Study of Vidaza and Velcade (Bortezomib) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

CALGB-10502 Dose escalation and phase II study of bortezomib (IND #58443, NSC #681239) added to standard daunorubicin and cytarabine therapy for patients with previously untreated acute myeloid leukemia age 60-75 years

OSU-07067 Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis.

OSU-07131A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion in Combination with Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD

OSU-08071 Expanded Access Study of Plerixafor and G-CSF for the Mobilization and Collection of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma, Hodgkin's Disease or Multiple Myeloma

OSU-08092 Defibrotide for Hematopoietic Stem Cell Transplant (SCT) Patient with Severe Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study

OSU-08127 A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) from Unrelated Donors in Patients with Hematologic Malignancies

OSU-08194 An Open-label, Dose-escalation, Phase I Study of IMC-EB10 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

OSU-09029 A Phase III Randomized, Multicenter Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate as Graft-Versus-Host Disease (GVHD) Prophylaxis After HLA-Matched, Related Peripheral Blood Stem Cell Transplantation

OSU-09015 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response.

OSU-07069 Myeloproliferative Disorder Research Consortium (MPD-RC) Research Tissue Bank

OSU-08109 A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis

OSU-08144 Phase 2 Study of SCH 727965 in Subjects with Relapsed and Refractory Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia

OSU-09034 Phase II study of 5-azacytidine and lintuzumab in myelodysplastic syndromes (MDS)

OSU-09150 Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia

OSU-10093 A Phase I study of azacitidine in combination with MEC (mitoxantrone, etoposide, cytarabine) in relapsed and refractory acute myeloid leukemia

CALGB-100701 Phase II study of reduced intensity allogeneic stem cell transplant for high-risk chronic lymphocytic leukemia (CLL)

CALGB-10801 A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib (NSC#732517, IND #73969) in Newly Diagnosed Patients with Core Binding Factor Acute Myeloid Leukemia (AML)

CALGB-100601 Reduced-intensity allogenic hematopoietic cell transplantation as second transplantation for patients with disease relapse or myelodysplasia after prior autologous transplantation

OSU-09139 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 (brentuximab vedotin) and Best Supportive Care (BSC) versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma (HL) Following Autologous Stem Cell Transplant (ASCT)

OSU-10079 A Phase I Study of Lenalidomide Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Patients with Select High Risk Hematological Malignancies

OSU-10016 Phase I Study of Lenalidomide and Conventional Chemotherapy in Relapsed or Refratory Acute Myeloid Leukemia

OSU-09111Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia

OSU-09143 A Phase III Multi-center Randomized Trial Comparing Tacrolimus/Sirolimus/Methotrexate versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis after Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation for Patients with Lymphoma

SWOG-S0535-Phase II study of ATRA, Arsenic Trioxide and Gematuzumab Ozogamicin in pts with previously untreated high risk APL.

OSU-08094 Phase I, Multicenter, Dose Escalation Trial Evaluating Maximum Tolerated Dose of Single and Repeated Administration of Allogeneic MultiStem in Patients with Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia

OSU-10007 An Open-label, Uncontrolled, Multicenter, Multinational Study on the Efficacy and Safety of Administration of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR), through the use of TH9402 and Light Treatment in an Ex Vivo Process, in Patients Receiving a CD34-selected Peripheral Blood Stem Cell Graft from a Related, Haploidentical Donor

OSU-11087 A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications

OSU-11052 A Phase 1, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

CALGB-21003 Embedded Companion to CALGB-11001

CALGB-11001 A PHASE II STUDY INCORPORATING SORAFENIB (IND 69896, NSC 724772) INTO THE THERAPY OF PATIENTS ¡Ý 60 YEARS OF AGE WITH FLT3 MUTATED ACUTE MYELOID LEUKEMIA

CALGB-21101 Embedded Companion to CALGB-11002

CALGB-211006 Embedded Companion to CALGB-11002

CALGB-11002 A RANDOMIZED PHASE II TRIAL OF DECITABINE-BASED INDUCTION STRATEGIES FOR PATIENTS 60 YEARS OLD WITH ACUTE MYELOID LEUKEMIA (AML)

OSU-10068 An open-label treatment-option protocol of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma or relapsed or refractory systemic anaplastic large cell lymphoma

OSU-10073 A Phase III Randomized, Multicenter Trial Testing Whether Exercise or Stress Management Improves Functional Status and Symptoms of Autologous and Allogeneic Recipients

OSU-11065 An Exploratory Phase 1/2 Clinical Trial Evaluating ALD518 in subjects with Glucocorticoid-Refractory Acute Graft vs. Host Disease (GVHD) after Allogeneic Hematopoetic Stem Cell Transplant (HSCT)

OSU-11111 ERWINASE®MASTER TREATMENT PROTOCOL

CALGB-100801 Phase II Study of the Addition of Azacitidine (IND #87574, NSC #102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients with AML

OSU-11013 A Phase 1, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate-2 or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

OSU-11004 Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease(GVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT)

OSU-10081 A phase 1b, dose-finding study of oral panobinostat (LBH589) in combination with idarubicin and cytarabine induction and high-dose cytarabine-based consolidation therapy in adult patients less than or equal to 65 years old with acute myeloid leukemia (AML)

OSU-11163 A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Hodgkin Lymphoma

OSU-11021 Research database for undiagnosed cytopenias.

OSU-12006 A Phase I, open, cohort dose escalation trial with BI 836858 in patients with refractory or relapsed acute myeloid leukemia

OSU-09135 Phase II, Randomized, Double-Blind Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera.

OSU-06072 A phase I, multi-dose study of SGN-33 (antihuCD33 mAb; HuM195; lintuzmab) in patients with acute myeloid leukemia and myelodysplastic syndrome

OSU0515- A phase II study of BMS-354825 in subjects with myeloid blast phase chronic myeloid leukemia resistant to or intolerant of imatinib mesylate

OSU-05072 A randomized two-by-two, multicenter, open-lable, phase II study of BMS-354825 administered orally at a dose of 70mg twice daily or 140mg once daily in subjects with chronic myeloid leukemia in accelerated phase or in myeloid or lymphoid blast phase or with philadelphia chromosome positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib (gleevec)

OSU05071- A randomized two-by-two, multicenter, open-label, phase III study of BMS-354825 administered orally at a dose of 50mg or 70mg twice daily or 100mg or 140mg once daily in subjects with chronic phase phildelphia chromosome or BRC_ABL positive chonic myelogenous leukemia who are resistant or intolerant to imatinib mesylate (gleevec)

OSU-05014 A phase II study of BMS-354825 in subjects with accelerated phase chronic myeloid leukemia resistant to or intolerant of imatinib

OSU-05013 A phase II stufy to determine the activity of BMS-354825 in subjects with chronic phase philadelphia chromosome-positive chronic myeloid leukemia who have disease that is resistant to high dose imatinib mesylate (gleevec) or who are intolerant of imatinib

OSU-05012 A randomized multi-center open label study of BMS-354825 vs. imatinib mesylate (gleevec) 800 mg.d in subjects with chronic phase philadelphia chromosome-positive chromis myeloid leukemia who have disease that is resistant to imatinib at a dose at 400-600 mg/d

OSU-04112 A phase II study of BMS-354825 in subjects with lymphoid blast phase chronic myeloid leukemia of philadelphia chromosome positive acture lymphoblastic resistent ro or intolerant of imatinib mesylate

OSU-08137 Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients who have Received Prior Therapy with ATRA and Arsenic Trioxide (STAR-1)

OSU-07090 Leuprolide (LHRH Agonist) to Enhance Immune function Post-Autologous Stem Cell Transplantation

OSU-08121A program for monitoring minimal residual disease following treatment of patients w/Acute Myeloid Leukemia or High Grade myelodysplastic syndrome

 

Conferences

Vasu S, Jaglowski SM, Geyer S, Bingman A, Elder P, Yu J, Andritsos LA, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Lozanski G. "Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)." In BLOOD. (November 2012). abstract #4192-.

Hamadani HM, Craig M, Remick S, Gibson L, Petros W, Abraham J, Cumpston A, Bunner P, Basu S,Tse H, Hennelly C, Vasu S, Klisovic RB, Blum W, Jaglowski SM, Benson DM, Andritsos LA, Penza S, Hofmeister CC, Geyer S, Devine SM, Efebera YA. "Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT)." In BLOOD. (November 2012). abstract #1942-.

Klisovic RB, Wang H, Walker A, Walsh K, Vasu S, Garzon R, Devine SM, Wang J, Garr C, Norris A, Byrd JC, Grever MR, Blum W, Chan KK, Marcucci G. "Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results." In BLOOD. (November 2012). abstract #3616-.

Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Uv V, Liu Z, Schwind S, Mims AS, Klisovic,Rebecca R, Walker A, Grever MR, Villalona-Calero M, Byrd JC, Garzon R, Blum W, Chan KK, Marcucci G. "Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)." In BLOOD. (November 2012). abstract #3578-.

Jaglowski SM, Vasu S, Geyer S, Bingman A, Elder P, Yu J, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Andritsos LA, Lozanski G. "Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease." In BLOOD. (November 2012). abstract #1949-.

Blum W, Klisovic RB, Walker A, Schwind S, Jiang Y, Wang J, Phelps M, Geyer S, Devine SM, Walsh K, Vasu S, Curfman JP, Schaaf L, Garr C, Kefauver C, Byrd JC, Grever MR, Garzon R, Marcucci G. "Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.." In BLOOD. (November 2012). abstract #2619-.

 

Degrees

1993 B.S., Case Western Reserve University

1997 M.D., The Ohio State University

 

Editorial Activities

2007 Blood
2007 American Journal of Hematology
2007 Cancer Research
 

Honors

1989 - 1993 Ohio Leadership Awards.
1990 - 1993 CWRU Student Leadership Awards.
1992 Tau Beta Pi, Honorary Engineering Society.
1993 Katona Award for Excellence in Biomedical Engineering.
1993 Michelson-Morley Undergraduate Research Prize. Michelson-Morley.
1997 OSU College of Medicine Outstanding Senior Award.
1998 The Whitehead Society Outstanding Intern Award.
2002 AACR workshop "Molecular Biology in Clinical Oncology", selected participant.
2002 ASCO Merit Award.
2002 T32 Fellowship Award.
2010 Certificate of Excellence,Outstanding Achievement in Patient Service. The James Cancer Hospital.
 

Journal Articles

Marcucci, Guido; Bruner, Rebecca J.; Binkley, Philip F.; Xiao, Jim; Chan, Kenneth K.; Parthun, Mark; Davis, Melanie; Fischer, Beth; Shank, Roshini; Moran, Mollie; Byrd, John C.; Grever, Michael. "Phase I Trial of the Histone Deacetylase Inhibitor Depsipeptide (FR901228) in Acute Myeloid Leukemia (AML).." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 317-.

Griffin, John H.; Leung, Joey; Bruner, Rebecca J.; Caligiuri, Michael A.; Briesewitz, Roger. "Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.." Proceedings of the National Academy of Sciences of the United States of America. Vol. 100, no. 13. (January 2003.): 7830-7835.

Shea, Thomas, C; Bruner, Rebecca; Wiley, Joseph, M; Serody, Jonathan, S; Sailer, Scott; Gabriel, Don, A; Capel, Eileen; Moore, Dominic, T; Dent, Georgette; Bentley, Stuart; Brecher, Mark E. "An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies.." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Vol. 9, no. 7. (January 2003.): 443-52.

De Angelo, Daniel J.; Stone, Richard M.; Bruner, Rebecca J.; Caligiuri, Michael A.; Heaney, Mark L.; Nimer, Stephen D.; Paquette, Ronald; Sawyers, Charles L.; Lambing, Joe L.; Lokker, Nathalie A.; Giese, Neill A.; Sinha, Vikram; Cooper, Michael R.; Druker, Brian J.; Heinrich, Michael C.. "Phase I clinical results with MLN518, a novel FLT3 antagonist: Tolerability, pharmacokinetics, and pharmacodynamics.." Blood. Vol. 102, no. 11. (January 2003.): 65a-66a.

Bruner, Rebecca J ; Farag, Sherif S.. Monoclonal antibodies for the prevention and treatment of graft-versus-host disease. Vol. 30, no. 4. (January 2003.): 509-519.

Marcucci,G; Stock,W; Dai,G; Liu,S; Klisovic,R; Klisovic,M,I; Sher,D; Huynh,L; FRANKEL,S; Blum,W; Larson,R,A; Grever,M,R; Byrd,J,C; Chan,K,K. "Intracellular levels of oblimersen sodium and target downregulation correlates to clinical activity of bcl-2 antisense in acute myeoid leukemia (AML).." BLOOD. Vol. 104, no. 11. (November 2004.): 331A-331A.

Marcucci,G; Stock,W; Dai,G; Klisovic,M,I; Maharry,K; Shen,T; Liu,S; Sher,D,A; Lucas,D; ZWIEBEL,A; Larson,R,A; Caligiuri,M,A; Bloomfield,C,D; Chan,K,K; Grever,M,R; Byrd,J,C. "G3139, a BCL-2 antisense oligo-nucleotide, in AML.." Annals of hematology. Vol. 83, (January 2004.): S93-4.

Whitman, Susan, P; Liu, Shujun; Vukosavljevic, Tamara; Rush, Laura, J; Yu, Li; Liu, Chunhui; Klisovic, Marko, I; Maharry, Kati; Guimond, Martin; Strout, Matthew, P; Becknell, Brian; Dorrance, Adrienne; Klisovic, Rebecca, B; Plass, Christoph; Bloomfield, Clara, D; Marcucci, Guido; Caligiuri, Michael A. "The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy.." Blood. Vol. 106, no. 1. (January 2005.): 345-52.

Byrd, John, C; Marcucci, Guido; Parthun, Mark, R; Xiao, Jim, J; Klisovic, Rebecca, B; Moran, Mollie; Lin, Thomas, S; Liu, Shujun; Sklenar, Amy, R; Davis, Melanie, E; Lucas, David, M; Fischer, Beth; Shank, Roshini; Tejaswi, Sooraj, L; Binkley, Philip; Wright, John; Chan, Kenneth, K; Grever, Michael R. "A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.." Blood. Vol. 105, no. 3. (January 2005.): 959-67.

Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novic S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, and Byrd JC. "Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity." J Clin Oncol. Vol. 23, no. 15. (January 2005.): 1-7.

Whitman,S,P; Liu,S,J; Vukosavljevic,T; Rush,L,J; Yu,L; Liu,C,H; Klisovic,M,I; Maharry,K; Guimond,M; Strout,M,P; Becknell,B; Dorrance,A; Klisovic,R,B; Plass,C; Bloomfield,C,D; Marcucci,G; Caligiuri,M,A. "The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy." BLOOD. Vol. 106, no. 1. (July 2005.): 345-352.

Byrd,J,C; Marcucci,G; Parthun,M,R; Xiao,J,J; Klisovic,R,B; Moran,M; Lin,T,S; Liu,S,J; Sklenar,A,R; Davis,M,E; Lucas,D,M; Fischer,B; Shank,R; Tejaswi,S,L; Binkley,P; Wright,J; Chan,K,K; Grever,M,R. "A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia." BLOOD. Vol. 105, no. 3. (February 2005.): 959-967.

Neviani,P; Santhanam,R; Trotta,R; Notari,M; Blaser,B,W; Liu,S,J; Mao,H; Chang,J,S; Galietta,A; Uttam,A; Roy,D,C; Valtieri,M; Bruner-Klisovic,R; Caligiuri,M,A; Bloomfield,C,D; Marcucci,G; Perrotti,D. "The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein." CANCER CELL. Vol. 8, no. 5. (November 2005.): 355-368.

Liu,Shujun; Pang,Jiuxia; Yu,Jianhua; Liu,Zhongfa; Huynh,LeNguyen; Kearney,Jessica; Paschka,Peter; Klisovic,Rebecca,B; Baiocchi,Robert; Blum,William; Perrotti,Danilo; Marcucci,Guido. "Bortezomib-induced down-regulation of KIT is mediated by inhibition of Sp1 and NF-kB in AML1/ETO-positive cells.." BLOOD. Vol. 108, no. 11. (November 2006.): 132B-132B.

DeAngelo,Daniel,J; Amrein,Philip,C; Kovacsovics,Tibor,J; Klisovic,Rebecca,B; Powell,Bayard,L; Cooper,Michael; Webb,Iain,J; Stone,Richard,M. "Phase 1/2 study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML).." BLOOD. Vol. 108, no. 11. (November 2006.): 51A-51A.

Blum,William; Marcucci,Guido; Devine,Hollie; Klisovic,Rebecca. "Imatinib mesylate-induced complete cytogenetic response in acute myeloid leukemia with t(5;12)(q33;p13).." BLOOD. Vol. 108, no. 11. (November 2006.): 181B-181B.

Blum,William; Klisovic,Rebecca,B; Kefauver,Cheryl; Johnson,Amy; Phelps,Mitch; Dalton,James,T; Lucas,David; Huynh,Le,Nguyen; Liu,Shujun; Grever,Michael,R; Colevas,A,D; Marcucci,Guido; Byrd,John,C. "Updated results of a phase I study of flavopiridol in acute leukemias using a novel, pharmacolkinetically derived schedule: Clinical activity including hyperacute tumor lysis syndrome (TLS), pharmacokinetics (PIC), and pharmacodynamics (PD).." BLOOD. Vol. 108, no. 11. (November 2006.): 224B-224B.

Ali,Naeem,A; O'Brien,James,M; Blum,William; Klisovic,Rebecca,B; Marcucci,Guido; Phillips,Gary; Marsh,Clay,B; Lemeshow,Stanley; Byrd,John,C; Grever,Michael,R. "Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.." BLOOD. Vol. 108, no. 11. (November 2006.): 476B-476B.

Sun,Jin; Liu,Shujun; Yu,Jianhua; Wei,Min; Mao,Charlene; Ding,Haiming; Kearney,Jessica; Huynh,LeNguyen; Paschka,Peter; Wang,Dachun; Klisovic,Rebecca,B; Perrotti,Danilo; Chen,Ching-Shih; Blum,Williom,George; Marcucci,Guido. "Characterization of HDACI OSU42 as a novel histone deacetylase inhibitor in AML cell lines.." BLOOD. Vol. 108, no. 11. (November 2006.): 563A-563A.

DeAngelo,Daniel,J; Stone,Richard,M; Heaney,Mark,L; Nimer,Stephen,D; Paquette,Ronald,L; Klisovic,Rebecca,B; Caligiuri,Michael,A; Cooper,Michael,R; Lecerf,Jean-Michel; Karol,Michael,D; Sheng,Shihong; Holford,Nick; T Curtin,Peter; Druker,Brian,J; Heinrich,Michael,C. "Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics." BLOOD. Vol. 108, no. 12. (December 2006.): 3674-3681.

Liu, Zhongfa; Liu, Shujun; Xie, Zhiliang; Blum, William; Perrotti, Danilo; Paschka, Peter; Klisovic, Rebecca; Byrd, John; Chan, Kenneth, K; Marcucci, Guido. "Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.." Nucleic acids research. Vol. 35, no. 5. (January 2007.): -.

Liu S, Klisovic RB , Vukosavljevic T, Yu J, Paschka P, Huynh L, Pang J, Liu Z, Neviani P, Blum W, Chan KK, Perrotti D, and Marcucci G. "Targeting AML1/ETO-HDAC repressor complex: a novel mechanism for valproic acid mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells." J Pharmacol Exp Ther. Vol. 321, no. 3. (January 2007.): 953-960.

Ali NA, O’Brien JM, Blum W, Byrd JC, Klisovic RB, Marcucci G, Phillips G, Marsh CB, Lemeshow S, Grever MR. "Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality." Cancer. Vol. 110, no. 1. (January 2007.): 96-102.

Blum W, Klisovic RB , Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G. "Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia." J Clin Oncol. Vol. 25, no. 25. (January 2007.): 3884-3891.

Cheng, Hao; Liu, Zhongfa; Blum, William; Byrd, John, C; Klisovic, Rebecca; Grever, Michael, R; Marcucci, Guido; Chan, Kenneth K. "Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS.." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. Vol. 850, no. 1-2. (January 2007.): 206-212.

Klisovic,Rebecca,B; Coutre,Steven; Kovacsovics,Tibor,J; Kantarjiam,Hagop,M; Tricot,Guido,J; Strovel,Jeffrey,W; Genna,Thomas; Bol,David,K; Hamilton,Michael; Mitchell,Beverly,S. "Clinical-biomarker correlations in adult AML patients in a phase I trial of AVN944 support observations of clinical effect and provide hypotheses for patient selection criteria for further clinical trials." BLOOD. Vol. 110, no. 11. (November 2007.): 273A-274A.

Blum,William; Klisovic,Rebecca,B; Johnson,Amy; Kefauver,Cheryl; Phelps,Mitch; Lucas,David; Huynh,LeNguyen; Liu,Shujun; Dalton,James,T; Grever,Michael,R; Marcucci,Guido; Byrd,John,C. "Final results of a dose escalation study of flavopiridol in acute leukemias using a novel-treatment schedule." BLOOD. Vol. 110, no. 11. (November 2007.): 272A-272A.

Hamadani,Mehdi; Elder,Patrick; Awan,Farrukh; Krugh,David; Blum,William; Lin,Thomas; Andritsos,Leslie; Bechtel,Thomas; Blum,Kristie; Klisovic,Rebecca; Devine,Steven,M. "High rates of early donor chimerism and low risk of chronic GVHD can be achieved in poor risk patients undergoing unrelated donor stem cell transplantation using a reduced intensity conditioning regimen incorporating fludarabine, busulfan, and rabbit ATG." BLOOD. Vol. 110, no. 11. (November 2007.): 351B-351B.

Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G. "A Phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase I, in patients with high-risk myelodysplasia and acute myeloid leukemia." Clinical Cancer Research. no. 14(8): 2444-9. (January 2008.): -.

Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Elder P, Blum K, Penza S, Lin TS, Klisovic RB, Marcucci G, Farag SS, Devine SM. "Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogenic peripheral blood cell transplantation.." Biol Blood Marrow Transplant. Vol. 14, no. 7. (January 2008.): 783-9.

Blum,William; Klisovic,Rebecca; Liu,Shujun; Garzon,Ramiro; Kefauver,Cheryl; Liu,Zhongfa; Mickle,Jon; Devine,Hollie; Devine,Steve; Grever,Michael,R; Chan,Kenneth,K; Villalona-Calero,Miguel; Byrd,John,C; Marcucci,Guido. "Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age >= 60) with Previously Untreated Acute Myeloid Leukemia (AML)." BLOOD. Vol. 112, no. 11. (November 2008.): 1016-1016.

Wei X, Dai G, Liu Z, Cheng H, Xie Z, Klisovic R, Marcucci G, Chan K. "Enzyme kinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleatide reductase.." http://dmd.aspetjournals.org. Vol. 36, no. 11. (January 2008.): 2227-2233.

Klisovic RB , Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan KK, Marcucci G. "Phase I study of GTI-2040, an anti-sense to ribonucleotide reductase, in combination with high dose cytarabine in patients with acute myeloid leukemia." Clin Cancer Res. Vol. 14, no. 12. (January 2008.): 3889-3895.

Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehman E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caliguiri MA, Chan KK, Wu LC, Marcucci G. "Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methytransferase activity in acute myeloid leukemia.." Blood. Vol. 11, no. 4. (January 2008.): 2364-73.

Klisovic,Rebecca,B; Stock,Wendy; Cataland,Spero; Klisovic,Marko,I; Liu,Shujun; Bium,William; Green,Margaret; Odenike,Olatoyosi; Godley,Lucy; Burgt,Jennifer,Vanden; Van Laar,Emily; Cullen,Michael; MacLeod,A,Robert; Besterman,Jeffrey,M; Reid,Gregory,K; Byrd,John,C; Marcuccil,Guido. "A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia." CLINICAL CANCER RESEARCH. Vol. 14, no. 8. (April 2008.): 2444-2449.

Hamadani M; Blum W; Phillips G; Elder P; Andritsos L; Hofmeister C; O'Donnell L; Klisovic R; Penza S; Garzon R; Krugh D; Lin T; Bechtel T; Benson DM; Byrd JC; Marcucci G; Devine SM. "Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.." Biology Of Blood And Marrow Transplantation: Journal Of The American Society For Blood And Marrow Transplantation. Vol. 15, no. 11. (November 2009.): 1422-.

Chen P, Liu Z, Liu S, Xie Z, Aimiuwu J, Pang J, Klisovic R , Blum W, Grever MR, Marcucci G, Chan KK. "A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels." Pharm Res. Vol. 26, no. 6. (March 2009.): 1504-1515.

Chen,Ping; Blum,William; Aimiuwu,Josephine; Upadhyayula,Vijayasarathi; Liu,Zhongfa; Liu,Shujun; Pang,Jiuxia; Walker,Alison; Klisovic,Rebecca,B; Garzon,Ramiro; Grever,Michael,R; Villalona-Calero,Miguel; Byrd,John,C; Chan,Kenneth,K; Marcucci,Guido. "Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine." BLOOD. Vol. 114, no. 22. (November 2009.): 1454-1455.

Chandler,Jason,C; Klisovic,Rebecca,B; Phelps,Mitch,A; Walker,Alison; Garzon,Ramiro; Yang,Xiaoxia; Schaaf,Larry; Schwind,Sebastian; Becker,Heiko; Liu,Shujun; Hickey,Chris; Kefauver,Cheryl; Mickle,Jon; Devine,Steven,M; Grever,Michael,R; Byrd,John,C; Marcucci,Guido; Blum,William. "Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia." BLOOD. Vol. 114, no. 22. (November 2009.): 346-347.

Blum,William; Klisovic,Rebecca,B; Walker,Alison; Garzon,Ramiro; Liu,Shujun; Schaaf,Larry,J; Humphries,Kristina; Grever,Michael,R; Devine,Steven,M; Byrd,John,C; Marcucci,Guido. "Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML)." BLOOD. Vol. 114, no. 22. (November 2009.): 815-816.

Blum W, Klisovic RB , Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC. "Dose escalation of lenalidomide in relapsed or refractory acute leukemias." J Clin Onc. Vol. 28, no. 33. (November 2010.): 4919-4925.

Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC.. "Dose escalation of lenalidomide in relapsed or refractory acute leukemias." J Clin Oncol. Vol. 28, no. 33. (November 2010.): 4919-25.

W. Blum, MA Phelps, RB Klisovic, DM Rozewski, W Ni, KA Albanese, B Rovin, C Kefauver, SM Devine, DM Lucas, A Johnson, LJ Schaaf, JC Byrd, G Marcucci, MR Grever. "Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.." Haematologica. Vol. 95, no. 7. (May 2010.): 1098-1105.

Blum,William; Klisovic,Rebecca,B; Garzon,Ramiro; Walker,Alison; Schwind,Sebastian; Liu,Shujun; Schaaf,Larry; Garr,Celia; Devine,Steven,M; Greyer,Michael,R; Byrd,John,C; Marcucci,Guido. "Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)." BLOOD. Vol. 116, no. 21. (November 2010.): 1349-1349.

Blum W; Garzon R; Klisovic RB; Schwind S; Walker A; Geyer S; Liu S; Havelange V; Becker H; Schaaf L; Mickle J; Devine H; Kefauver C; Devine SM; Chan KK; Heerema NA; Bloomfield CD; Grever MR; Byrd JC; Villalona-Calero M; Croce CM; Marcucci G. "Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.." Proceedings Of The National Academy Of Sciences Of The United States Of America. Vol. 107, no. 16. (April 2010.): 7473-.

Chen P, Aimiuwu J, Xie Z, Wei X, Liu S, Klisovic R , Marcucci G, Chan KK. "Biochemical modulation of Aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 leukemia cells." AAPS. Vol. 13, no. 1. (March 2011.): 131-140.

Rondelli,Damian; Goldberg,Judith,D; Marchioli,Roberto; Isola,Luis; Shore,Tsiporah,B; Prchal,Josef,T; Bacigalupo,Andrea; Rambaldi,Alessandro; Klisovic,Rebecca,B; Gupta,Vikas; Andreasson,Bjorn; Demakos,Erin,P; Price,Leah,S; Scarano,Marco; Wetzler,Meir; Vannucchi,Alessandro,M; Najfeld,Vesna; Barosi,Giovanni; Silverman,Lewis,R; Hoffman,Ronald. "Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis." BLOOD. Vol. 118, no. 21. (November 2011.): 763-763.

KH Metzeler, A Walker, S Geyer, R Garzon, RB Klisovic , CD Bloomfield, W Blum, and G Marcucci. "DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia." Leukemia. Vol. 26, no. 5. (January 2011.): 1106-1107.

Walker,Alison,R; Metzeler,Klaus,H; Geyer,Susan; Becker,Heiko; Schwind,Sebastian; Whitman,Susan,P; Curfman,John; Wu,Yue-Zhong; Perrotti,Danilo; Klisovic,Rebecca,B; Garzon,Ramiro; Blum,William; Marcucci,Guido. "Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute-Myeloid Leukemia (AML)." BLOOD. Vol. 118, no. 21. (November 2011.): 430-430.

Blum,William; Schwind,Sebastian; Tarighat,Somayeh,S; Geyer,Susan; Eisfeld,Ann-Kathrin; Whitman,Susan; Walker,Alison; Klisovic,Rebecca; Byrd,John,C; Santhanam,Ramasamy; Wang,Hongyan; Curfman,John,P; Devine,Steven,M; Jacob,Samson; Garr,Celia; Kefauver,Cheryl; Perrotti,Danilo; Chan,Kenneth,K; Bloomfield,Clara,D; Caligiuri,Michael,A; Grever,Michael,R; Garzon,Ramiro; Marcucci,Guido. "Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia." BLOOD. Vol. 119, no. 25. (June 2012.): 6025-6031.

Aimiuwu,Josephine; Wang,Hongyan; Chen,Ping; Xie,Zhiliang; Wang,Jiang; Liu,Shujun; Klisovic,Rebecca; Mims,Alice; Blum,William; Marcucci,Guido; Chan,Kenneth,K. "RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.." Blood. Vol. 119, no. 22. (May 2012.): 5229-5238.

Ranganathan,Parvathi; Yu,Xueyan; Na,Caroline; Santhanam,Ramasamy; Shacham,Sharon; Kauffman,Michael; Walker,Alison; Klisovic,Rebecca; Blum,William; Caligiuri,Michael; Croce,Carlo,M; Marcucci,Guido; Garzon,Ramiro. "Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.." Blood. Vol. 120, no. 9. (August 2012.): 1765-1773.

Yan,Pearlly; Frankhouser,David; Murphy,Mark; Tam,Hok-Hei; Rodriguez,Benjamin; Curfman,John; Trimarchi,Michael; Geyer,Susan; Wu,Yue-Zhong; Whitman,Susan,P; Metzeler,Klaus; Walker,Alison; Klisovic,Rebecca; Jacob,Samson; Grever,Michael,R; Byrd,John,C; Bloomfield,Clara,D; Garzon,Ramiro; Blum,William; Caligiuri,Michael,A; Bundschuh,Ralf; Marcucci,Guido. "Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia." BLOOD. Vol. 120, no. 12. (September 2012.): 2466-2474.

Huang,Xiaomeng; Schwind,Sebastian; Yu,Bo; Santhanam,Ramasamy; Wang,Hongyan; Hoellerbauer,Pia; Mims,Alice; Klisovic,Rebecca; Walker,Alison,R; Chan,Kenneth,K; Blum,William; Perrotti,Danilo; Byrd,John,C; Bloomfield,Clara,D; Caligiuri,Michael,A; Lee,Robert,J; Garzon,Ramiro; Muthusamy,Natarajan; Lee,Ly,James; Marcucci,Guido. "Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia." CLINICAL CANCER RESEARCH. Vol. 19, no. 9. (May 2013.): 2355-2367.

Mendler JH, Maharry K, Becker H, Eisfeld, AK, Senter L, Mrózek K, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Khalife J, Caligiuri MA, Klisovic RB, Moore JO, Carter TH, Marcucci G, Bloomfield CD. "In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.." Haematologica. Vol. 98, no. 8. (August 2013.): e92-4.

Mims,A; Walker,A,R; Huang,X; Sun,J; Wang,H; Santhanam,R; Dorrance,A,M; Walker,C; Hoellerbauer,P; Tarighat,S,S; Chan,K,K; Klisovic,R,B; Perrotti,D; Caligiuri,M,A; Byrd,J,C; Chen,C-S; Lee,L,James; Jacob,S; Mrozek,K; Bloomfield,C,D; Blum,W; Garzon,R; Schwind,S; Marcucci,G. "Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia." Leukemia. Vol. 27, no. 4. (April 2013.): 871-878.

Wang,Hongyan; Chen,Ping; Wang,Jiang; Santhanam,Ramasamy; Aimiuwu,Josephine; Saradhi,U,VVijaya; Liu,Zhongfa; Schwind,Sebastian; Mims,Alice; Byrd,John,C; Grever,Michael,R; Villalona-Calero,Miguel,A; Klisovic,Rebecca; Walker,Alison; Garzon,Ramiro; Blum,William; Chan,Kenneth,K; Marcucci,Guido. "In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia." AAPS JOURNAL. Vol. 15, no. 1. (January 2013.): 242-249.

 

Reference Works

January 1992 Panigutti MA, Merritt K, Bruner RJ, Kraay MJ, Brown SA."Correlation of allergy metal levels, implant alloy, and implant damage in patients undergoing revision joint anthroplasty." .
January 1992 Bruner RJ, Merritt K, Brown SA, Panigutti MA."Incidence of allergy in patients undergoing total joint revision." .
January 1993 Bruner RJ, Merritt K, Brown SA, Kraay MJ."Metal sensitivity in patients undergoing total joint revision." .
January 1995 Shoemaker LH, Bruner RJ, Fristad M, Cromer B."Primary health care problems in adolescents with psychiatric disorders." .
January 2000 Gabriel DA, Shea T, Wiley J, Serody J, Kirby S, Bruner RJ, Capel E, Bigelow S, Morris D, Banderencko N, Brecher M."Use of amifostine to reduce mucositis following total brain irradiation-based autotransplants for lymphoma." .
January 2002 Whitman SP, Guimond M, Blaser B, Klisovic M, Vukosavlijevic T, Bruner RJ, Ruppert AS, Becknell B, Barbosa X, Griffen J, Briesewitz R, Caliguiri."Primary acute myeloid leukemia cells with the FLT3 internal tandem duplication (ITD) and absence of wild-type (WT) FLT3 (FLT3 Genotype) are distinct from AML with either FLT3 or FLT3 genotypes." .
January 2002 De Angelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette R, Klisovic RB, Caligiuri MA, Cooper MR, LeCerf J-M, Lyer G, Heinrich MC, Druker BJ."Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with Acute Myeloid Leukemia (AML)" .
January 2002 Bruner RJ, Marcucci G, Binkley P, Xiao J, Chan K, Parthun M, Davis M, Fischer B, Shank R, Moran M, Grever M, Byrd JC."Phase I trial of the histone deacetylase inhibitor depsipeptide (FR901228) in fludarabine refactory chronic lymphocytic leukemia." .
January 2002 Bruner RJ, Marcucci G, Binkley P, Xiao J, Chan K, Parthun M, Davis M, Fischer B, Shank R, Maran M, Grever M, Byrd JC."Phase I trial of the histone deacetylase inhibitor depsipeptide (FR901228) in Fludarabine Refactory Chronic Lymphocytic Leukemia" .
January 2002 Bruner RJ, Marcucci G, Binkley P, Fischer B, Parthun M, Davis M, Xiao J, Chan K, Wright J, Grever M, Byrd JC."A phase I study to determine minimally effective pharmacologic dose (MEPD) of depsipeptide (FR901228) in selected hematologic malignancies." .
January 2002 Sooraj LN, Marcucci G, Byrd JC, Bruner RJ, Fischer B, Hatton P, Grever M, Binkley PF."Cardiovascular response to depsipeptide: Absense of cardiotoxicity in human recipients." .
January 2002 Marcucci G, Bruner RJ, Binkley PF, Xia J, Chan KK, Parthun M, Davis M, Fischer B, Shank R, Mroan M, Byrd JC, Grever M."Phase I trial of the histone deacetylase inhibitor depsipeptide (FR901228) in acute myeloid leukemia." .
January 2003 Whitman SP, Liu S, Klisovic MI, Vukosavljevic T, Guimond M, Rush LJ, Ruppert AJ, Strout MP, Becknell B, Dorrance AM, Bruner RJ, Plass C, Bloomfield CD, Marcucci G, Caliguiri M."Activation of the silenced MLL (ALL-1) wild-type allele in Acute Myeloid Leukemia (AML) with the MLL partial tandem duplication results in enhancement of cell death." .
January 2003 De Angelo DJ, Stone RM, Bruner RJ, Caliguiri MA, Heaney ML, Nimer SD, Paquette R, Sawyers CL, Lambing JL, Lokker NA, Giese NA, Sinha V, Cooper MR, Druker BJ, Heinrich MC."Phase I clinical results with MLN518, a novel FLT3 antagonist: tolerability, pharmacokinetics, and pharmacodynamics." .
January 2004 Marcucci G, Stock W, Dai G, Liu S, Klisovic RB, Klisovic MI, Sher D, Huynh L, Frankel S, Blum W, Larson RA, Grever M, Byrd JC, Chan KK."Intracellular levels of oblimersen sodium and target downregulation correlates to clinical activity of bcl-2 antisense in Acute Myeloid Leukemia (AML)" .
January 2005 Neviani P, Santhanam R, Trotta R, Notari M, Blaser B, Chang J, Liu S, Mao K, Oaks J, Roy D, Valtieri M, Klisovic RB, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D."Resetting PP2A tumor suppressor activity overcomes BCR/ABL leukemogenic potential in blast crisis CML" .
January 2005 Klisovic RB, Blum W, Wei X, Liu S, Kefauver C, Huynh L, Zwiebel JA, Byrd JC, Grever M, Marcucci G."A phase I study of GTI-2040, and antisense to Ribonucleotide Reductase (RNR) in combination with High-Dose Cytarabine (HiDAC) in relapsed or refactory Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and clinical results." .
January 2005 Blum W, Klisovic RB, Liu S, Byrd JC, Liu Z, Chan KK, Kefauver C, Huynh L, Grever MR, Marcucci G."Phase I study of low dose decitabine in patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and clinical activity." .
January 2006 Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, Dalton JT, Lucas D, Colevas AD, Grever M, Marcucci G, Byrd JC."Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemias: Clinical efficacy including hyperacute tumor lysis, phamacokinetics, and pharmacodynamics." .
November 2006 Sun J, Liu S, Yu J, Wei M, Moa C, Ding H, Kearney J, Huynh L, Paschka P, Wang D, Klisovic Rb, Perrotti D, Chen C, Blum W, Marcucci G."Characterization of HDACI OSU42 as a Novel Histone Deacetylas Inhibitor in AML cell lines." .
January 2006 Marcucci G, Klisovic RB, Wei E, Liu S, Liu Z, Chan K, Plass C, Grever MR, Chan K, Blum W."A phase I study of GTI-2040 (6), an antisense to ribonucleotide reductase (RNR), in combination with high-dose AraC (HiDAC) in acute myeloid leukemia (AML)" .
November 2006 DeAngelo D, Amrein P, Kovacsovics T, Klisovic RB, Powell B, Cooper M, Webb I, Stone R.."Phase 1/2 study of Tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML)." .
November 2006 Blum W, Marcucci G, Devine H, Klisovic RB.."Imatinib Mesylate-Induced complete cytogenetic response in AML Myeloid Leukemia with t(5;12)(q33;p13)" .
November 2006 Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, Dalton J, Lucas D, Huynh L, Liu S, Grever M, Colevas A, Marcucci G, Byrd J.."Updated results of a phase I study of Flavopiridol in acute leukemias using a novel, pharmacokinetically derived scheduled clinical activity including hyperacute Tumor Lysis Syndrome (TLS) Pharmacokinetics (PK), and Phamacodynamics (PD)" .
November 2006 Ali N, O'Brien J, Blum W, Klisovic RB, Marcucci G, Phillips G, Marsh C, Lemeshow S, Byrd J, Grever M."Hyperglycemia in patients with acute myeloid leukemia is associated with increrased hospital mortality" .
January 2006 Klisovic RB, Blum W, Hackanson B, Kefauver C, Liu s, Liu Z, Chan K, Plass C, Grever M, Byrd JC, Marcucci G."Updated results of a phase I study of low dose decitabine and valporic acid (VA) in patients with acute myeloid leukemia (AML): Gene reexpression, demethylation and clinical response." .
November 2006 Liu S, Pang J, Yu J, Liu Z, Huynh L, Paschka P, Klisovic RB, Baiocchi R, Blum W, Perrotti D, Marcucci G."Bortezomib-induced down-regulation of KIT is mediated by inhibition of Sp1 and KF-kB in AML1/ETO-postive cells" .
November 2007 Blum W, Klisovic RB, Johnson A, Kefauver C, Phelps M, Lucas D, Huynh L, Liu S, Dalton J, Grever M, Marcucci G, Byrd J."Final results of a dose escalation study of Flavopiridol in acute leukemias using a novel treatment schedule." .
November 2007 Klisovic RB, Coutre S, Kovacsovics T, Kantarjiam H, Tricot G, Strovel J, Genna T, Krugh D, Hamilton M, Mithcell B."Clinical - Biomarker correlations in adult AML patients in a phase I trial of AVN944 support observations of clinical effect and proven hypotheses for patient selection criteria for further clinical trials" .
November 2007 Hamadani M, Elder P, Awan F, Krugh D, Blum W, Lin T, Andritsos L, Bechtel T, Blum K, Klisovic RB, Devine S.."High rates of early donor chimerism and low risk of chronic GV van be achieved in poor risk patients undergoing unrelated do stem cell transplantation using reduced intensity conditioning regimen incorporating Fludarabine, Busulfan, and Rabbit ATG" .
January 2007 Klisovic RB, Tricot G, Coutre S, Kovacsovics T, Genna T, Bol D, Strovel J, Hamilton M, Mitchell B."A phase I trial of AVN944 in patients with advanced hematologic malignancies." .
May 2008 Blum W, Andritsos L, Johnson A, Klisovic RB, Kefauver C, Devine S, Marcucci G, Byrd J."Preliminary results of a phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL); evidence of activity in acute myeloid leukemia (AML) toxicity in CLL starting dose." .
November 2008 Blum W, Klisovic RB, Liu S, Garzon R, Kefauver C, Liu Z, Mickle J, Devine H, Devine S, Grever M, Chan K, Villalona-Calero M, Byrd J, Marcucci G.."Preliminary results of a Phase II study of low dose decitabine as a single agent in older patients (age>60) with previously untreated acute myeloid leukemia (AML)." Washington D.C.
November 2008 Odenike O, Godwin J, Van Besien K, Huo D, Sher d, Burke P, Smith S, Green M, Melnick J, Wade J, Lester E, Klisovic RB, Baer M, Larson R, Stock W.."Phase II trial of low-dose, subcutaneous decitabine in Myelofibrosis." Washington D.C.
January 2009 Blum W, Klisovic RB, Walker A, Garzon R, Liu S, Schaaf LJ, Humphries K, Grever MR, Devine SM, Byrd JC, Marcucci G."Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia" New Orleans.
January 2009 Chen P, Blum W, Aimiuwu J, Upadhyayula V, Liu Z, Liu S, Pang J, Walker A, Klisovic RB, Garzon R, Grever MR, Villalona-Calero M, Byrd JC, Chan KK, Marcuccu G."Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine" New Orleans.
January 2009 Chandler JC, Klisovic RB, Phelps MA, Walker A, Garzon R, Yang Xiaoxia, Schaff L, Schwind S, Becker H, Lui S, Hickey C, Kefauver C, Mickle J, Devine SM, Grever MR, Byrd JC, Marcucci G, Blum W."Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myleoid Leukemia" New Orleans.
May 2009 Blum WG, Klisovic R, Liu S, Kefauver C, Grever MR, Schaaf L, Chan K, Byrd JC, Villalona-Calero M, Marcucci G."Efficacy of a novel schedule of decitabine in previously untreated AML, age 60 or older" .
April 2009 Aimiuwu J, Chen P, Xie Z, Liu Z, Sarathi V, Liu S, Klisovic RB, Marcucci G, Chan K.."In vitro-in vivo pharmacodynamic analisis of GTI-2040 combined with Arc-C acute myeloid leukemia." .
December 2010 D. Rondelli, M.W. Boyer, L. M. Isola, T. Shore, A. Bacigalupo, R.B. Klisovic, R. Marchiloli, J.D. Goldberg, R. Hoffman, L.R. Silverman,."First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in United States: interim analysis of MPD-RC 101 protocol" Chicago.
November 2010 William Blum, Rebecca B. Klisovic , Ramiro Garzon, Alison Walker, Sebastian Schwind, Shujun Liu, Larry Schaaf, Celia Garr, Steven M. Devine, Michael R. Grever, John C. Byrd, and Guido Marcucci."Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)" Orlando.
January 2011 Alison R. Walker, Klaus H. Metzeler, Susan Geyer, Heiko Becker, Sebastian Schwind, Susan P. Whitman, John Curfman, Yue-Zhong Wu, Danilo Perrotti, Rebecca B. Klisovic , Ramiro Garzon, William Blum, and Guido Marcucci."Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML)" .
January 2011 Damiano Rondelli, Judith D. Goldberg, Roberto Marchioli, Luis Isola, Tsiporah B. Shore, Josef T. Prchal, Andrea Bacigalupo, Alessandro Rambaldi, Rebecca B. Klisovic , Vikas Gupta, Bjorn Andreasson, Erin P. Demakos, Leah S. Price, Marco Scarano, Meir Wetzler, Alessandro M. Vannucchi, Vesna Najfeld, Giovanni Barosi, Lewis R. Silverman, and Ronald Hoffman."Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis" .
January 2011 KH Metzeler, A Walker, S Geyer, R Garzon, RB Klisovic,CD Bloomfield, W Blum and G Marcucci."DNMT3A mutations and response to the hypomethylating agentdecitabine in acute myeloid leukemia" .
March 2012 Alice S. Mims, Alison R. Walker, Hongyan Wang, Xiaomeng Huang, Ramasamy Santhanam, Pia Hoellerbauer, Somayeh Tarighat, Kenneth K. Chan, Rebecca B. Klisovic, Danilo Perrotti, Michael A. Caligiuri, John C. Byrd, Ching-Shih Chen, William Blum, Ramiro Garzon, Sebastian Schwind, and Guido Marcucci.."AR-42, a Histone Deacetylase Inhibitor, increases microRNA-29b and sensitizes cells to decitabine treatment: a novel epigenetic-targeting approach in Acute Myeloid Leukemia." Philadelphia.
February 2012 J. Cooper, D. Krugh, J. Duda, J. Roddy, R. Klisovic, M. Lamprecht, J. Beavers-Kirby, C. Hofmeister, J. Dishon-Ritzert, S. Devine."Improving Vaccination of Patients Pre and Post Bone Marrow Transplant." San Diego.
February 2012 Damiano Rondelli, Judith D. Goldberg, Roberto Marchioli, Luis Isola, Tsiporah B. Shore, Josef T. Prchal, Andrea Bacigalupo, Alessandro Rambaldi, Rebecca B. Klisovic , Vikas Gupta, Bjorn Andreasson, Erin P. Demakos, Leah S. Price, Marco Scarano, Meir Wetzler, Alessandro M. Vannucchi, Vesna Najfeld, Giovanni Barosi, Lewis R. Silverman, and Ronald Hoffman."Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis" San Diego.
March 2012 Schwind S, Samadzadeh S, Geyer S, Klisovic RB, Eisfeld A, Walker A, Whitman S,Ramasamy S, Wu Y, Samson J, caligiuri M, Grever M, Perrotti D, Byrd J, Garzon R, Boomfield C."The Combination of Bortezomib (BOR) and Decitabine (DEC): a Phase I Trial in Patients (Pts) with Acute Myeloid Leukemia (AML) targeting FLT3 expression" Chicago.

Presentations

"Idiopathic Hypereosinophilic Syndrome: Potential new treatment and clues to Pathogenesis." Presented at OSU Medical Center Grand Rounds, . (October 2002)

"A Phase I Study of GT12040 in combination with high-dose Cytarabine in refactory or relapsed AML." Presented at NCI CTEP, . (September 2005)

"Clinical Update on CML." Presented at Chillicothe VA Lecture Series, . (August 2005)

"CML." Presented at Upper Valley Medical Center Grand Rounds, . (October 2009)

"Chronic Myeloid Leukemia and Myeloproliferative Disorders." Presented at OSU ASH Review, . (January 2009)

"Chronic Myeloid Leukemia." Presented at OSU American Society of Cancer Review, Columbus, OH. (January 2011)

"Hematology Highlights." Presented at ASCO Review, Columbus, OH. (June 2012)

"Updates in AML." Presented at Leukemia and Lymphoma Society/Genesis Healthcare, . (October 2012)

"Acute Leukemia." Presented at The Ohio State University ASH Review, . (January 2013)

"Chronic Myeloid Leukemia (CML)." Presented at The Nexus, . (April 2013)

"Hematolgy Updates." Presented at American Society of Clinical Oncology (ASCO) Review, . (June 2013)

"Myelofibrosis (MF)." Presented at CME Program, KnowledgeOncology, . (July 2013)